美国预防服务工作组:衣原体与淋病筛查推荐声明
USPSTF基于系统综述更新2014年推荐,评估性活跃青少年和成人(含孕妇)衣原体与淋病筛查的获益与危害。结论为对24岁及以下所有性活跃女性及25岁及以上感染风险升高女性筛查衣原体和淋病均有中等净获益(B推荐),男性筛查证据不足(I声明)。
要点
- 24岁及以下所有性活跃女性应筛查衣原体和淋病(B推荐)。
- 25岁及以上感染风险升高的女性应筛查衣原体和淋病(B推荐)。
- 男性衣原体和淋病筛查的获益与危害证据不足(I声明)。
核心结论
- USPSTF以中等确定性认为,对24岁及以下所有性活跃女性及25岁及以上感染风险升高女性筛查衣原体和淋病具有中等净获益。
- 当前证据不足以评估男性衣原体和淋病筛查的获益与危害平衡。
研究设计与样本
- USPSTF委托系统综述,评估性活跃青少年和成人(含孕妇)衣原体和淋病筛查的获益与危害,以更新2014年推荐。
- 目标人群为无症状、性活跃的青少年和成人,包括孕妇。
主要发现
- 女性衣原体和淋病感染常无症状,可能导致盆腔炎性疾病及其相关并发症。
- 孕妇未治疗感染所生新生儿可能发生新生儿衣原体肺炎或淋球菌性或衣原体性眼炎。
- 男性感染可能导致尿道炎和附睾炎,两类感染均可增加HIV感染或传播风险。
关键数值与推荐
- 对24岁及以下所有性活跃女性筛查衣原体:B推荐。
- 对25岁及以上感染风险升高女性筛查衣原体:B推荐。
- 对24岁及以下所有性活跃女性筛查淋病:B推荐。
- 对25岁及以上感染风险升高女性筛查淋病:B推荐。
- 男性衣原体和淋病筛查:I声明(证据不足)。
临床怎么用
- 对24岁及以下所有性活跃女性常规筛查衣原体和淋病。
- 对25岁及以上女性,若评估为感染风险升高则筛查衣原体和淋病。
- 男性是否筛查应结合个体情况判断,因当前证据不足以支持普遍筛查。
局限性
- 男性筛查获益与危害的现有证据不足,无法形成推荐。
- 推荐基于中等确定性证据,净获益评估为中等而非高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chlamydia and gonorrhea are among the most common sexually transmitted infections in the US. Infection rates are highest among adolescents and young adults of both sexes. Chlamydial and gonococcal infections in women are usually asymptomatic and may lead to pelvic inflammatory disease and its associated complications. Newborns of pregnant persons with untreated infection may develop neonatal chlamydial pneumonia or gonococcal or chlamydial ophthalmia. Infection in men may lead to urethritis and epididymitis. Both types of infection can increase risk of acquiring or transmitting HIV. OBJECTIVE: To update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for chlamydia and gonorrhea in sexually active adolescents and adults, including pregnant persons. POPULATION: Asymptomatic, sexually active adolescents and adults, including pregnant persons. EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit. The USPSTF concludes with moderate certainty that screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. RECOMMENDATION: The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation) The USPSTF recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. (I statement).
引用
- Davidson KW, Barry MJ, Mangione CM, et al. Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. 2021. PMID: 34519796. doi:10.1001/jama.2021.14081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。